康容注射注液降低颅内压作用的临床研究  被引量:28

Clinical Study of Effect of Kangrong Injection on Intracranial Pressure in patients with Brain Injury

在线阅读下载全文

作  者:林欣[1] 苏晨芳[1] 张赛[1] 焦德让[1] 王实[1] 毛瑞 

机构地区:[1]天津环湖医院神经外科,天津300060

出  处:《中国临床神经外科杂志》2004年第3期190-192,共3页Chinese Journal of Clinical Neurosurgery

摘  要:目的探讨康容注射液降低颅内压的效果。方法颅脑损伤引起的颅内压增高病人62例,随机平均分为实验组和对照组。实验组静脉快速输注20%康容注射液,对照组静脉快速输注20%甘露醇。所有病人均进行连续的颅内压监护,并同时观察其可能出现各种副作用。结果实验组显效4例,有效12例,进步13例,无效2例;对照组显效2例,有效13例,进步13例,无效3例。两组的总有效率分别为93.5%(29/31)和90.3%(28/31),相差无显著性(P>0.05)。在用药期间和用药后两组均没有观察到与所用药品有关的副作用。结论康容注射液具有与甘露醇相同的降颅内压效果,且无明显副作用,在临床上可用于降低各种原因引起的颅内压升高。Objective To explore the effect of Kangrong injection on intracranial pressure (ICP). Methods Sixty-two patients with high ICP induced by brain injury randomly were averagely divided into both the experimental and control groups. Kangrong injection was rapidly infused into patient's vein in the experimental group, and mannitol injection was rapidly infused into patient's vein in the control group. The ICP in the patients of both the groups was consecuratively monitored. The possible side effects of Kangrong and mannitol were observed at the same time. Results Of 31 patients of experimental group, 4 had excellent outcome, 12 good, 13 fair and 2 bad. Of 31 patients of the control group, 2 had excellent outcome, 13 good, 13 fair and 3 bad. The total effective rate (93.5%, 29/31) in the experimental group was insignificantly different (P>0.05) from that (90.3%, 28/31) in the control group. No notable side effects were observed in both the experimental and control groups during and after the administering the drugs. Conclusion Kangrong injection may be clinically used for reducing the high ICP produced by various diseases because its curative effect on high ICP is similar to mannitol injection and it has no notable side effects.

关 键 词:康容注射液 甘露醇 颅脑损伤 颅内压 

分 类 号:R651.15[医药卫生—外科学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象